Abstract During catabolism of tryptophan through the kynurenine (KYN) pathway, several endogenous metabolites with neuromodulatory properties are produced, of which kynurenic acid (KYNA) is one of the highest significance. The causal role of altered KYNA production has been described in several neurodegenerative and neuropsychiatric disorders (e.g., Parkinson's disease, Huntington's disease, schizophrenia) and therefore kynurenergic manipulation with the aim of therapy has recently been proposed. Conventionally, KYNA is produced from its precursor L-KYN with the aid of the astrocytic kynurenine aminotransferase-2 (KAT-2) in the murine brain. Although the mouse is a standard therapeutic research organism, the presence of KAT-2 in mice has not been described in detail. This study demonstrates the presence of kat-2 mRNA and protein throughout the adult C57Bl6 mouse brain. In addition to the former expression data from the rat, we found prominent KAT-2 expression not only in the astrocyte, but also in neurons in several brain regions (e.g., hippocampus, substantia nigra, striatum, and prefrontal cortex). A significant number of the KAT-2 positive neurons were positive for GAD67; the presence of the KAT-2 enzyme we could also demonstrate in mice brain homogenate and in cells overexpressing recombinant mouse KAT-2 protein. This new finding attributes a new role to interneuron-derived KYNA in neuronal network operation. Furthermore, our results suggest that the thorough investigation of the spatio-temporal expression pattern of the relevant enzymes of the KYN pathway is a prerequisite for developing and understanding the pharmacological and transgenic murine models of kynurenergic manipulation.
Introduction
Tryptophan (TRP) is catabolized mostly through the kynurenine pathway (KP) in the mammalian brain (Gal and Sherman 1980) . Kynurenic acid (KYNA) is a neuroactive end-product of this metabolic route, and it exerts multiple effects on ligand-gated ion channels in the brain (Gal and Sherman 1980; Birch et al. 1988; Prescott et al. 2006; Albuquerque and Schwarcz 2013) It is also an endogenous, agonistic ligand of the G-protein-coupled receptor 35 (GPR35) primarily in peripheral tissues but also in the central nervous system (Berlinguer-Palmini et al. 2013; Alkondon et al. 2015) .
Altered level of brain KYNA is implicated in the pathophysiology of several neuropsychiatric disorders such as Huntington's disease (Stoy et al. 2005 ), Alzheimer's disease (Gulaj et al. 2010) , and schizophrenia (Erhardt et al. 2001; Linderholm et al. 2012) .
The manipulation of the kynurenine system with the aim of therapy has been widely studied recently (Vecsei et al. 2013) . However, no detailed anatomical study describing the spatio-temporal expression pattern of KYN pathway enzymes has been performed alongside the genetic and pharmacological studies.
KYNA is synthesized with the irreversible transamination of L-kynurenine (L-KYN) and is excreted into blood without further metabolism. KYN-KYNA transformation is catalyzed by kynurenine aminotransferases (KATs), of which KAT-2 is of greatest importance both in the murine and human brain (Guidetti et al. 2007a ). Based on the anatomical studies performed in rats (Okuno et al. 1990; Guidetti et al. 2007b) , the prevailing view is that KAT-2 is localized in astrocytes and KYNA is produced and released by this cell type (Guillemin et al. 2001 ). However, it has been reported that KAT-2 or its isoforms localized also in rat and human neuronal cell cultures (Rzeski et al. 2005; Guillemin et al. 2007) and in the Ammon's horn in the rat hippocampus (Okuno et al. 1990; Du et al. 1992) . Moreover, neuronal localization of KATs was detected outside the rat brain, specifically in the medulla and spinal cord (Kapoor et al. 1997) and in the inner retina (Rejdak et al. 2001) .
Little is known about the mechanism and regulation of KYNA transport in the brain nor is it known how cells liberate KYNA. KYNA uptake by human and rat organic anion transporters (hOAT and rOAT) was shown using Xenopus laevis oocytes (Uwai et al. 2013) . KYNA release from rat astrocyte and neuron cell culture and from rat brain slices has also been reported (Turski et al. 1989; Rzeski et al. 2005) , but the details of these mechanisms are unknown.
Although investigating the role of the KP in neurodegenerative and neuropsychiatric diseases in mice is of great relevance, most of the data regarding the expression profile of KAT-2 and transport mechanism of KYNA are derived from rat and human samples. To our best knowledge, no description about the localization and distribution of KAT-2 in the mouse brain is available in the literature.
The aim of this study was to clarify the presence of kat-2 mRNA and protein in adult mouse brain tissue. We examined the expression of kat-2 mRNA with in situ hybridization and we performed fluorescent immunohistochemistry to identify KAT-2 containing cells in brain structures in which the role of KYNA related to neuropsychiatric disorders has been proposed formerly. To verify the specificity of the primary anti-KAT-2 antibody, we performed Western blot analysis on mouse brain homogenate and on homogenate of cells transfected with mouse kat-2 cDNA.
In addition to KAT-2 containing astrocytes, we found prominent neuronal enzyme localization in the substantia nigra, while neuronal expression of KAT-2 was sporadic in the hippocampus, striatum, and prefrontal cortex. Interestingly, the vast majority of the KAT-2 containing neurons were interneuron in all brain areas. Taken together, our data indicate that KYNA synthesis and release may also be relevant in neurons in mice. This new finding attributes a new role to brain KYNA in network operation.
Materials and methods

Animals
For the histological and molecular studies, 8 week-old male C57Bl/6 mice obtained from The National Institute of Oncology (Budapest, Hungary) were used (n = 6). Animals were kept under controlled laboratory conditions and had free access to food and water. All experiments were in compliance with the guidelines of the European Communities Council Directives (2010/63/EU) and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 32. §), and were approved by the ethical license: I-74-16/ 2015.
Tissue preparation
Animals were deeply anesthetized with an intraperitoneal injection of urethane (1.6 g/bwkg) and were perfused transcardially with ice-cold 0.1 M phosphate buffer (PB, pH 7.4) following 4 % paraformaldehyde (dissolved in 0.1 M PB, pH 7.4) for the immunohistochemical experiments. The brains were removed and post-fixed overnight in 4 % paraformaldehyde. 20-lm sagittal (for immunohistochemistry) and 30-lm coronal (for in situ hybridization) sections were obtained with a vibratome (Leica VT1000S). For the Western blot analysis, animals were perfused with cold 0.1 M PB (pH 7.4) and the brains were processed immediately on ice, as described below.
All solutions were treated with diethylpyrocarbonate (DEPC) to avoid RNAse contamination during RNA in situ hybridization.
Labeled RNA probe design kat-2 cDNA clone (Aadat NM 011834 Mouse cDNA clone, OriGene Technologies) was removed from its vector with KpuI and HindIII digestion. The resulted 1600-bp fragment was amplified with kat-2-specific primers carrying T7 or SP6 RNA polymerase promoter sequences. The primer sequences were as follows: 5 0 -GGA TCC TAA TAC GAC TCA CTA TAG GGA GAA CCA GAG GGA TTC CAT A-3 0 (KAT-2 forward) and 5 0 -GGA TCC ATT TAG GTG ACA CTA TAG AAG AGG AAA GCT ATT TGG CAA TGT G-3 0 (KAT-2 reverse). Sense and antisense probes were synthesized with the aid of in vitro transcription using the amplified DNA templates, the T7 or SP6 RNA polymerase (Sigma-Aldrich) and digoxigenin (DIG)-labeled nucleotides (DIG RNA Labeling mix, Sigma-Aldrich).
RNA in situ hybridization
For detection of kat-2 mRNA, in situ hybridization was performed. Sections were extensively washed in DEPCtreated PB containing 0.2 % Tween-20 (PBT, pH 7.4), digested with proteinase K (2 lg/ml, Sigma-Aldrich) for 5 min and post-fixed with 4 % PFA for 20 min. After thorough washing in PB, slices were prehybridized for 1 h at 65°C in hybridization buffer containing 50 % formamide, 5 9 saline-sodium citrate (SSC), 0.1 mg/ml sonicated chicken DNA, 0.1 % Tween-20, and 0.1 M citrate (pH 4.5) and then hybridized overnight at 65°C in the same solution containing the DIG-labeled sense or antisense probe for kat-2 mRNA (*300 ng/ml). Next day, stringent washes were performed in descending concentrations of the hybridization buffer, then sections were blocked with 1 % normal donkey serum (NDS) and incubated in AP-conjugated anti-DIG antibody (sheep anti-DIG-AP, 1:1000, Sigma-Aldrich) overnight on 4°C. The following day samples were exposed to the NBT-BCIP substrate (1:50, pH 9.5, Sigma-Aldrich). Enzymatic reaction was stopped with PB (pH 7.4) and sections were coverslipped with aqueous mounting medium (SigmaAldrich).
Immunohistochemistry
Free-floating sections were washed in PBT and incubated in 1 % NDS. For the detection of KAT-2 and identification of the cells containing the enzyme, sections were exposed to the primary antibodies (rabbit anti KAT-2, 1:1000, Proteintech; rat anti-GFAP, 1:4000, Sigma; mouse antiNeuN, 1:4000, Millipore and mouse anti-GAD67, 1:1000, Millipore) overnight at 4°C. Next day, samples were incubated in the appropriate secondary antibodies (1:500; Jackson Immuno Research) at room temperature (RT). Primary and secondary antibodies were diluted in 0.1 M PBT containing 1 % NDS. Negative control was prepared from sections incubated without the primary antibodies. The sections were coverslipped with antifade mounting medium (ProLong Ò Gold, Life Technologies). Fluorescent photomicrographs were obtained with an Olympus BX51 microscope fitted with a DP70 digital imaging system.
Results
kat-2 mRNA expression
To study kat-2 mRNA localization in the mouse brain, we performed RNA in situ hybridization. kat-2 mRNA expression was prominent throughout the brain both in the white and gray matter. We detected significant labeling in several brain areas, including the CA1 subfield of hippocampus (Fig. 1) . A large fraction of the labeled cells showed small and dense astrocytic-like cell bodies in the CA1 and also in the corpus callosum. Another cell population expressing kat-2, pronouncedly in the pyramidal cell layer, had large and pale neuron-like somata (Fig. 1b, c) . No signal was detected when brain sections were hybridized with kat-2 sense probes (Fig. 1a) .
KAT-2 protein expression
The presence of KAT-2 was studied with double fluorescent immunolabeling. KAT-2 was widely distributed in the whole mouse brain.
Similar to previous observations achieved in rats (Guidetti et al. 2007b) , we found pronounced KAT-2 immunopositivity in astrocytes in several brain areas in mice. As illustrated in Fig. 2 , KAT-2 was co-localized with the astrocytic marker GFAP in all layers of the CA1 subregion of the hippocampus and was expressed mostly in the somatic region and in the primary branches of the astrocytes. Additionally, there were a large number of ? , but GFAP -star-shaped cells with highly branched processes, e.g., in the mouse striatum and prefrontal cortex. These cells are presumably astrocytes with low levels of GFAP (Supp. Fig. 1 ). KAT-2 positivity in astrocytes was also prominent in the white matter of the mouse brain (see in Fig. 4a, b) , which coincides with the results of in situ hybridization. Furthermore, KAT-2 was detected in glial end-feet surrounding blood vessels. This phenomenon supports the astrocytic expression of the enzyme (Fig. 3) .
Unexpectedly, we detected large number of KAT-2 containing neurons in the mouse brain tissue. We confirmed the neuronal expression of the enzyme with KAT-2-NeuN double labeling. Neurons expressing KAT-2 distributed sporadically in the CA1 area of the hippocampus, dorsal striatum, and all layers of the medial prefrontal cortex (Fig. 4a, b, d) , whereas there was a significant number of ? /NeuN ? cells in the substantia nigra pars compacta and reticulata (Fig. 4c) . KAT-2 is expressed predominantly in the cell bodies of the neurons. To identify the neuron type, we performed GAD67 immunolabeling. KAT-2 and GAD67 were co-localized almost completely in the hippocampus, dorsal striatum, and medial prefrontal cortex (Fig. 5a, b, d ). GAD67
? and KAT-2 ? cells were also completely overlapping in the substantia nigra pars reticulata, while none of the KAT-2 ? neurons expressed GAD67 in the pars compacta subregion (Fig. 5c ). These findings indicate that most of the neurons are interneuron in the studied brain regions, suggesting an important role of interneuronal KYNA synthesis.
Finally, we tested whether the neuronal localization of KAT-2 is specific for mice or if it is phylogenetically conserved in rodents. Therefore, we examined the presence of KAT-2 in adult male Wistar rats (Charles-River). We found similar astrocytic and neuronal expression pattern of KAT-2 in the rat brain (Supp. Fig. 2 ). No staining was detected when primary antibodies were omitted. Fig. 1 Expression of kat-2 mRNA transcripts in the hippocampal CA1 subfield. No signal was detected in the CA1 subregion, when the brain sections were hybridized with the kat-2 sense probes (negative control) (a). Using antisense kat-2 probes, kat-2 mRNA expression was prominent in the whole mouse brain, including the CA1 subfield of the hippocampus (b). kat-2 mRNA is localized in small and dense astrocyte like cell bodies (arrows) and also in bigger and pale, neuron-like somata (arrowheads) through the CA1 subregion. The most significant neuronal kat-2 positivity was detected in the pyramidal cell layer of the CA1. kat-2 expression in astrocyte like somata was strong also in the cc (c). Scale bars are 200 lm in a and b and 50 lm in c. so str.oriens, sp str. pyramidale, sr str. radiatum, cc corpus callosum Fig. 2 Astrocytic localization of KAT-2 in the hippocampal CA1 subfield. Double labeling of KAT-2 (red) with the astrocyte marker GFAP (green) shows significant co-localization (orange) in all layer of the CA1 (left panel). KAT-2 is expressed mostly in the somatic region and in the primary branches of the astrocytes (right panels). Note the significant number of KAT-2 ? non-astrocytic cells in the sub and sporadically in the so, sp, sr, and slm of the CA1. Asterisk indicates the corresponding cell in lower and higher magnification photomicrographs (*). Scale bars are 80 lm (left panel) and 40 lm (right panels). sub subiculum, so str.oriens, sp str. pyramidale, sr str. radiatum, slm str. lacunosum-moleculare
Antibody validation
In addition to negative controls in immunohistochemistry, we tested the primary antibody specificity with Western blot analysis both on HeLa cell culture transfected with mouse kat-2 cDNA and on mouse brain tissue homogenate. The antibody recognized a single band in the transfected HeLa cell culture preparation at *47 kDa, which is the estimated size of KAT-2 (Supp. Fig. 3a) . We found similar clear positivity in mouse brain tissue homogenate (Supp. Fig. 3d ). Moreover, we performed immunocytochemistry on the HeLa cell culture. Large number of KAT-2 ? cells was seen in the transfected cell culture, while no positivity was observed in the control culture (Supp. Fig. 3b, c) . These data indicate that the primary antibody binds specifically to KAT-2 in the mouse brain tissue.
Discussion
KAT-2 is expressed by astrocytes and also by neurons in the mouse brain
In the present study, we demonstrated for the first time that KAT-2 is localized both in astrocytes and neurons in the adult mouse brain. The vast majority of these neurons were identified as GABAergic cells in the examined brain areas.
The antibody used against KAT-2 was validated on mouse brain tissue homogenate and also on HeLa cells transfected with mouse kat-2 cDNA and it showed appropriate specificity in both experiments.
Our observations are partially similar to previous data obtained from rats (Guidetti et al. 2007b ) and we found significant astrocytic expression of KAT-2 in the mouse hippocampus, striatum and cerebral cortex, and faint positivity in the substantia nigra. We could demonstrate the co-localization of KAT-2 and the astrocytic marker GFAP mostly in the hippocampus, while, e.g., in the striatum and prefrontal cortex a large number of KAT-2
? , but GFAP -cells were seen with astrocytic morphological features. Since GFAP expression in astrocytes of intact mouse cortex and striatum is very low (Kindy et al. 1992; Ben-Gigi et al. 2015) , we propose that these KAT-2 ? cells are astrocytes with undetectable levels of GFAP. Co-localization of the S100 astrocytic marker and KAT-2 in the striatum and cerebral cortex (unpublished data) supports this hypothesis. Furthermore, similar to previous reports from rats (Guidetti et al. 2007b ), we detected KAT-2 in astrocytic end-feet around brain capillaries. This feature of KAT-2 expression indicates the involvement of astrocytes in L-KYN uptake from blood similarly, as reported in rat (Speciale et al. 1989 ).
Similar to that described in rats Roberts et al. 1992) , sporadic neuronal KAT-2 immunoreactivity was seen in the mouse hippocampus, striatum, and prefrontal cortex. In other brain areas not investigated in former studies (e.g., in substantia nigra pars compacta and reticulata), we found more prominent neuronal KAT-2 expression. Neuronal presence of the enzyme was also significant in other parts of the brain not detailed in this study (e.g., cerebellum, thalamus) . Surprisingly, most of the KAT-2 ? neurons were positive for GAD67 interneuron marker in the examined brain areas. This characteristic feature of KAT-2 ? neurons has not been described in previous studies. Considering, that neurons synthesize KYNA at a rate about 2.3 times higher than astrocytes in vitro (Rzeski et al. 2005) , this cell population may have a significant role in KYNA synthesis in the brain.
The possible mechanism of KYNA release from interneurons and its significance in regulation of GABAergic cells
Previous studies indicate that KYNA is liberated from rat brain slices (Turski et al. 1989) and from neuronal and astrocytic cell cultures (Rzeski et al. 2005) . Our own observations also provide evidence that KYNA is released from mouse brain slices to the incubation medium (unpublished HPLC data). However, the exact mechanism of KYNA release from cells and the regulation of release are ? astrocyte end-feet surrounding blood vessels. Note the long process derives from an astrocyte and ends on the capillary (arrowhead) unknown. There is also no information on whether KYNA has a specific release site on these cells. The prominent interneuronal staining of KAT-2 raises the question of how this cell type liberates KYNA to the extracellular milieu. We detected KAT-2 in the somatic region of the interneurons, so one possible mechanism is that KYNA is released extrasynaptically from the neuronal cell bodies and it exerts a diffuse effect on the neighboring cell population.
Conventionally, the main ionotropic receptor targets of KYNA are the NMDA and the a7 nACh receptors, respectively. However, the interaction between KYNA and a7nACh receptors is controversial (Albuquerque and Schwarcz 2013) .
a7 nAChRs are widely distributed in the somato-dendritic compartments of interneurons, and also in the presynaptic terminals innervating interneurons in the hippocampus (Zarei et al. 1999; Kawai et al. 2002; . Moreover, GABAergic cells have tonically active NMDARs diffusely over the neuron, often at extrasynaptic locations (Povysheva and Johnson 2012; Hsieh et al. 2014 ). According to Riebe et al., tonically active extrasynaptic NMDARs contribute more prominently to the intrinsic excitation in GABAergic interneurons than in pyramidal cells. Authors showed that low concentrations of the NMDAR blocker memantine and phencyclidine preferentially inhibited tonically active extrasynaptic NMDAR on GABAergic cells (Riebe et al. 2016) .
The role of extrasynaptic NMDA receptors in transmitter release modulation has also been reviewed recently (Petralia 2012) . Considering these data, self-regulation of GABAergic cells and the concomitant alteration of GABAergic and glutamatergic neurotransmission (Erhardt et al. 2001 ) are also feasible through extrasynaptic KYNA release.
Impaired GABAergic neurotransmission is observed in pathological conditions, e.g., in schizophrenia, where NMDAR hypofunction affects primarily the GABAergic interneurons both in the hippocampus (Grunze et al. 1996) and in the prefrontal cortex (Homayoun and Moghaddam 2007) . This selectivity causes diminished inhibitory control and increased excitation by disinhibition over pyramidal neurons (Homayoun and Moghaddam 2007) . During schizophrenia the level of KYNA is abnormally increased (Schwarcz et al. 2001; Linderholm et al. 2012; Kegel et al. 2014) . Is it possible that extrasynaptically released KYNA acts on extrasynaptic NMDA and a7 nACh receptors, resulting in the downregulation of interneurons in schizophrenia? To test our hypothesis the exact mechanisms by which the endogenously produced KYNA is released from interneurons and also from astrocytes must be determined, both in physiological and pathological states.
Therapeutical manipulation of KAT-2 expression and KYNA synthesis in model animals of neuropsychiatric disorders Along with other KP metabolites, altered brain KYNA level is implicated in the pathogenesis of neurodegenerative diseases and mental disorders, like schizophrenia or major depressive disorder (Maddison and Giorgini 2015; Meier et al., 2016) . Therefore, manipulating KYNA synthesis or other branches of the KP holds broad therapeutic perspectives (Dounay et al. 2015) .
Recently the genetic Potter et al. 2010 ) and pharmacological (Zmarowski et al. 2009 , Koshy Cherian et al. 2014 ) inhibition of KAT-2 has been studied primarily for the treatment of psychiatric and cognitive disorders (Jayawickrama et al. 2015) . Kozak et al. (2014) showed that lowering KYNA level with selective KAT-2 inhibitor improves cognitive function under conditions considered relevant for schizophrenia in rats. On the other hand, shifting the KP toward KYNA synthesis with kynurenine 3-monooxygenase (KMO) inhibition prevents spatial memory deficits, anxiety-related behavior, and synaptic loss in a mouse model of Alzheimer's disease. These effects are proved to be related to the increasing extracellular brain levels of the neuroprotective KP metabolite KYNA (Zwilling et al. 2011) . Therefore, both upregulation and downregulation of KYNA production could serve as a potential therapeutical tool.
In the substantia nigra, we detected KAT-2 mostly in interneurons in the pars reticulata subregion, while astrocytes were only faintly positive for KAT-2. So it is conceivable that the decreased concentration of KYNA observed, e.g., in Parkinson's disease in this brain area (Ogawa et al. 1992) , is a consequence of neuronal KAT-2 dysfunction. Taking these results, astrocytes and neurons may have a distinctive role in disorders with abnormal brain KYNA level. Therefore, expression pattern and b Fig. 4 Neuronal localization of KAT-2 in the mouse hippocampus, striatum, substantia nigra, and prefrontal cortex. KAT-2 (red) is colocalized (orange) with the neuronal marker NeuN (green) in all the four brain areas shown in a-d. KAT-2 ? neurons are seen in all layer of the CA1 (so, sp, sr and slm) and also in the sub (a). The dorsal part of the striatum KAT-2 is also overlapped with NeuN in large striatal neurons (b). Neuronal KAT-2 expression is strong both in the SNc and SNr (c), while as in the hippocampus and striatum the enzyme is expressed sporadically in the medial prefrontal cortex (d). Note that KAT-2 is presented predominantly in the cell bodies of the neurons (right panels). Non-neuronal KAT-2 expression is detected in the examined brain areas and also in the cc (a-b). Asterisks indicate the corresponding cells in lower and higher magnification photomicrographs (*). Scale bars are 80 lm (left panels) and 40 lm (right panels). sub subiculum, so str.oriens, sp str. pyramidale, sr str. radiatum, slm str. lacunosum-moleculare, cc corpus callosum, SNr substantia nigra pars reticulata, SNc substantia nigra pars compacta activity of KAT-2 during neuropsychiatric disorders should be clarified before future therapeutical kynurenergic manipulation strategies are assigned.
Although the effect of genetic manipulations of the KYN pathway has been described in mice, the kat-2 knockout model suffers from the general limitations of the nullmutant models Yu et al. 2004 ). To understand tissue-and cell-type-specific function of KAT-2 in health and disease, one needs spatio-temporally selective kynurenergic manipulation, which is possible only if the expression profile of KAT-2 is well described in the wildtype animal.
Conclusion
In conclusion, we studied for the first time the expression profile of KAT-2 in the mouse brain. We proved that KAT-2 is expressed not only in astrocytes but also in neurons in brain structures in which the role of KYNA related to neuropsychiatric disorders has been proposed formerly. This result supports the growing body of evidence about neuronal KYNA synthesis and contradicts the previous common view that astrocyte is the only relevant KYNA producing cell type. The majority of KAT-2 containing neurons were interneuron in the examined brain areas. Brain structures composed predominantly of GABAergic neurons (e.g., the substantia nigra) possess the strongest neuronal KAT-2 expression. It is possible in these areas, that interneuronal KAT-2 production is superior to that of astrocyte both in physiological and pathological states. The release mechanism of KYNA is unknown, but the somatic location of the enzyme in the interneurons may indicate an extrasynaptic release mode, through which interneurons possibly control neighboring cell population including other interneurons and themselves as well.
Taken together, the release mechanisms of KYNA by these two distinct cell populations and the functional significance of the cell-type-specific expression of KAT-2 during neuropsychiatric disorders should be investigated in the future.
